User:Elizabeth Cook/Sandbox 1: Difference between revisions
From Proteopedia
Jump to navigationJump to search
No edit summary |
No edit summary |
||
| Line 38: | Line 38: | ||
== Disease and Therapeutics == | == Disease and Therapeutics == | ||
Abnormal regulation of CECR2 has been linked to several diseases. It was first studied in connection with Cat Eye Syndrome, a rare congenital disorder caused by duplication of a region on chromosome 22 that includes CECR2, leading to developmental abnormalities. More recently, CECR2 has been implicated in cancer, particularly in breast cancer metastasis, where it appears to promote tumor cell invasion and immune system evasion by altering gene expression patterns. Because CECR2 influences chromatin structure and gene activity, its dysregulation can have wide-ranging effects on development, immune response, and cancer progression, making it an important target for further research and potential therapies. CECR2 is an attractive drug target because of its bromodomain, as bromodomains already have many small molecule inhibitors in use clinically. | |||
In efforts to develop new small molecule inhibitors for the CECR2 bromodomain, Cpd6 has been found and studied. | |||
[[Image:Cecr2_contacts.png|center|400px|]] | [[Image:Cecr2_contacts.png|center|400px|]] | ||
Cpd6 makes contacts to CECR2 through N514 (2 direct H-bonds) and D646 (1 direct H-bond, and 1 H-bond coordinated by water). <ref>PMID:28740608</ref> | |||
<scene name='10/1079536/N514/1'>conserved asparagine</scene> | <scene name='10/1079536/N514/1'>conserved asparagine</scene> | ||
